Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis and characterized by various presentation, course, and response to treatment. A better understanding of the pathogenesis has led to the development of targeted therapeutic agents and innovative treatment stra...
Saved in:
| Main Authors: | N. A. Shostak, D. Yu. Andriyashkina, A. S. Dvornikov, N. M. Babadaev, D. V. Somov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-10-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CLINICAL HETEROGENEITY OF EARLY PSORIATIC ARTHRITIS
by: V. V. Badokin, et al.
Published: (2016-12-01) -
PSORIATIC ARTHRITIS: AN ALGORITHM FOR MAKING A DECISION ON THE CHOICE OF MANAGEMENT TACTICS
by: N. A. Shostak, et al.
Published: (2016-03-01) -
Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01) -
The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection
by: E. E. Gubar, et al.
Published: (2019-10-01) -
Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
by: Hideto Kameda, et al.
Published: (2025-03-01)